Search Results - "Fevzi Ersoy, F"

Refine Results
  1. 1

    Lymphocyte and monocyte vitamin D receptor expression during paricalcitol or calcitriol treatments in patients with stage 5 chronic kidney disease by Sözel, Hasan, Köksoy, Sadi, Ozdem, Sebahat, Yılmaz, Fatih, Bora, Feyza, Ersoy, F. Fevzi

    Published in International urology and nephrology (01-08-2020)
    “…Purpose In this study, we aimed to investigate the effect of paricalcitol and calcitriol usage on vitamin D receptor (VDR) contents of CD8+ , CD4+ lymphocytes…”
    Get full text
    Journal Article
  2. 2

    Peripheral Treg count and it’s determinants in unsensitized and sensitized chronic kidney disease patients by Topal, Cansu, Köksoy, Sadi, Süleymanlar, Gültekin, Yakuboğlu, Gülşen, Fevzi Ersoy, F.

    Published in International urology and nephrology (01-12-2013)
    “…Purpose Sensitization to HLA antigens resulting in anti-HLA antibodies (panel reactive antibodies; PRA) is a major problem in chronic kidney disease (CKD)…”
    Get full text
    Journal Article
  3. 3

    FGF-23, α-Klotho Gene Polymorphism and Their Relationship with the Markers of Bone Metabolism in Chronic Peritoneal Dialysis Patients by Yilmaz, Vural Taner, Ozdem, Sebahat, Donmez, Levent, Cetinkaya, Ramazan, Suleymanlar, Gultekin, Ersoy, F Fevzi

    Published in The Eurasian journal of medicine (01-06-2015)
    “…The aim of the present study was to evaluate the variations of some major bone metabolism markers with reference to klotho gene polymorphism (KGP) and bone…”
    Get full text
    Journal Article
  4. 4

    Osteoporosis in the elderly with chronic kidney disease by Ersoy, F Fevzi

    Published in International urology and nephrology (01-03-2007)
    “…Considering the aging dialysis population of today, increasing our knowledge about the nature, diagnosis and the treatment of bone mineral density (BMD)…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study by Koc, Hasan, Hoser, Hasan, Akdag, Yalcin, Kendir, Cemaliye, Ersoy, F. Fevzi

    Published in International urology and nephrology (01-07-2019)
    “…Objective To evaluate monthly percentage changes of intact parathyroid hormone (iPTH) and other major bone marker levels in patients with secondary…”
    Get full text
    Journal Article
  7. 7

    A short story of Klotho and FGF23: a deuce of dark side or the savior? by Ersoy, F. Fevzi

    Published in International urology and nephrology (01-03-2014)
    “…Fibroblast growth factor 23 (FGF23) is an osteocyte and osteoblast derived peptide hormone, which requires Klotho as a cofactor for its biologic actions. FGF23…”
    Get full text
    Journal Article
  8. 8

    IMPROVING TECHNIQUE SURVIVAL IN PERITONEAL DIALYSIS: WHAT IS MODIFIABLE? by Ersoy, F. Fevzi

    Published in Peritoneal dialysis international (01-02-2009)
    “…Akdeniz University Medical School, Department of Medicine, Division of Nephrology, Antalya, Turkey Correspondence to: F.F. Ersoy, Akdeniz University Medical…”
    Get full text
    Journal Article Conference Proceeding
  9. 9

    The influence of CTLA-4 single nucleotide polymorphisms on acute kidney allograft rejection in Turkish patients by Ruhi, Çağlar, Sallakçi, Nilgün, Yeğin, Olcay, Süleymanlar, Gültekin, Ersoy, F. Fevzi

    Published in Clinical transplantation (01-07-2015)
    “…Cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) is a cell surface protein, which down‐regulates the immune response at CTLA‐4/CD28/B7 pathway. We aimed to…”
    Get full text
    Journal Article
  10. 10

    Is Klotho F352V Polymorphism the Missing Piece of the Bone Loss Puzzle in Renal Transplant Recipients? by Ozdem, Sebahat, Yılmaz, Vural Taner, Ozdem, Sadi S, Donmez, Levent, Cetinkaya, Ramazan, Suleymanlar, Gultekin, Ersoy, F Fevzi

    Published in Pharmacology (01-01-2015)
    “…Bone disorders are next to cardiovascular problems in frequency in renal transplant (RT) recipients. Reduction in 1,25-dihydroxycholecalciferol (1,25D) levels…”
    Get more information
    Journal Article
  11. 11

    Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients by KOCAK, HUSEYIN, GUMUSLU, SAADET, SAHİN, EMEL, CEKEN, KAAN, GOCMEN, YESIM A, YAKUPOGLU, GULSEN, ERSOY, F FEVZI, TUNCER, MURAT

    Published in Nephrology (Carlton, Vic.) (01-04-2009)
    “…SUMMARY Aim:  Oxidative stress (OS) and asymmetric dimethylarginine (ADMA) are accepted as non‐classical cardiovascular risk factors in end‐stage renal disease…”
    Get full text
    Journal Article
  12. 12

    Use of peritoneal ultrafiltration in the elderly refractory congestive heart failure patients by Ruhi, Çağlar, Koçak, Hüseyin, Yavuz, Asuman, Süleymanlar, Gültekin, Ersoy, F. Fevzi

    Published in International urology and nephrology (01-06-2012)
    “…Background Refractory congestive heart failure (RCHF), due to its high mortality and hospitalization rates, is a growing health problem. In this study, as an…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15

    Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient by Yılmaz, Vural Taner, Koçak, Hüseyin, Avcı, Ali B., Salim, Ozan, Ersoy, Fevzi F., Süleymanlar, Gültekin

    Published in International urology and nephrology (01-06-2011)
    “…Thrombotic microangiopathy (TMA) in renal transplantation (RTX) generally develops during treatment with calcineurin inhibitors. We present a RTX case that…”
    Get full text
    Journal Article
  16. 16

    Uremic toxins: a new focus on an old subject by Yavuz, Asuman, Tetta, Ciro, Ersoy, F Fevzi, D'intini, Vincent, Ratanarat, Ranistha, De Cal, Massimo, Bonello, Monica, Bordoni, Valeria, Salvatori, Gabriella, Andrikos, Emilio, Yakupoglu, Gulsen, Levin, Nathan W, Ronco, Claudio

    Published in Seminars in dialysis (01-05-2005)
    “…The uremic syndrome is characterized by an accumulation of uremic toxins due to inadequate kidney function. The European Uremic Toxin (EUTox) Work Group has…”
    Get full text
    Journal Article
  17. 17

    THE VARIABILITY IN ULTRAFILTRATION ACHIEVED WITH ICODEXTRIN, POSSIBLY EXPLAINED by Venturoli, Daniele, Jeloka, Tarun K, Ersoy, Fevzi F, Rippe, Bengt, Oreopoulos, Dimitrios G

    Published in Peritoneal dialysis international (01-07-2009)
    “…Lund University Hospital, 1 Lund, Sweden; University of Toronto, 2 Toronto, Canada; Akdeniz University, 3 Antalya, Turkey Correspondence to: D. Venturoli,…”
    Get full text
    Journal Article
  18. 18

    Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods by Akbas, S. Halide, Ozdem, Sebahat, Caglar, Serkan, Tuncer, Murat, Gurkan, Alihan, Yucetin, Levent, Senol, Yesim, Demirbas, Alper, Gultekin, Meral, Ersoy, F. Fevzi, Akaydin, Mustafa

    Published in Clinical biochemistry (01-06-2005)
    “…Tacrolimus (FK506) is a potent immunosuppressive drug used for prevention of rejection following transplantation. Several methods including immunoassays have…”
    Get full text
    Journal Article
  19. 19
  20. 20

    The efficacy of urinalysis, plain films, and spiral CT in ED patients with suspected renal colic by Eray, Oktay, Çubuk, Metin S., Oktay, Cem, Yilmaz, Saim, Çete, Yildiray, Ersoy, F.Fevzi

    Published in The American journal of emergency medicine (01-03-2003)
    “…We determined the diagnostic value of urinalysis and plain films in patients with suspected renal colic presenting to an emergency department (ED). Over a…”
    Get full text
    Journal Article Conference Proceeding